Press Releases

Press Releases

Clinical Study to Test Modified Citrus Pectin in Prostate Cancer: Phase III Trial Now Recruiting Patients

Posted on Apr 4, 2014 | 4 comments

Clinical Study to Test Modified Citrus Pectin in Prostate Cancer: Phase III Trial Now Recruiting Patients

Clinical Study to Test Modified Citrus Pectin in Prostate Cancer: Phase III Trial Now Recruiting Patients   A phase III clinical trial is now recruiting participants to study the effects of PectaSol-C® modified citrus pectin (MCP) in controlling prostate specific antigen (PSA) levels in prostate cancer patients. The study, conducted at the Meir Medical Center in Kfar-Saba, Israel, will evaluate MCP’s efficacy for patients experiencing continued PSA increases in biochemical relapse of prostate cancer.   “MCP has shown activity against prostate and other cancers in a number of...

Read More

Breakthrough Study: Modified Citrus Pectin Boosts Chemo’s Power against Ovarian Cancer

Posted on Feb 7, 2014 | 1 comment

Breakthrough Study: Modified Citrus Pectin Boosts Chemo’s Power against Ovarian Cancer

New Breakthrough Study: Modified Citrus Pectin Boosts Chemo’s Power against Ovarian Cancer Ovarian cancer is one of the deadliest cancers because it’s often detected at a late stage, with higher risk of resistance to frontline chemotherapy drugs such as paclitaxel (commonly sold as Taxol). However, a new preclinical study from the University of Tehran and the Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, published in the Asian Pacific Journal of Cancer Prevention showed that Modified Citrus Pectin (MCP) increased the effectiveness of paclitaxel against ovarian cancer cells.

Read More

Modified Citrus Pectin Protects Against Vascular Hardening

Posted on Nov 21, 2012 | 28 comments

Modified Citrus Pectin Protects Against Vascular Hardening

The research on Modified Citrus Pectin (MCP) continues to grow, highlighting its powerful benefits against inflammation and the protein galectin-3 -- a culprit in heart disease, cancer, inflammation and fibrosis. In this powerful new study, published in Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, MCP blocked galectin-3 and reduced the inflammation, blood pressure, fibrosis and aortic wall thickness associated with vascular hardening and cardiovascular disease. Furthermore, MCP out-performed the pharmaceutical drug sprironolactone, safely without toxicity. Click here to read more about the study.

Read More

Botanical Formula Destroys Treatment-Resistant Breast Cancer in Mice

Posted on Nov 16, 2012 | 0 comments

Botanical Formula Destroys Treatment-Resistant Breast Cancer in Mice

A unique formula made from medicinal mushrooms, traditional Chinese herbs and other natural ingredients inhibits aggressive, human triple-negative breast cancer and breast-to-lung metastasis.

Read More

Powerful Botanical Formulas: New Weapons Against Cancer

Posted on Nov 16, 2012 | 20 comments

Powerful Botanical Formulas: New Weapons Against Cancer

Latest Data Shows How Botanical Formulas Safely Fight Cancer and Metastasis

Read More

Mind as Medicine: Retreat Brings Healing, Growth

Posted on Nov 16, 2012 | 1 comment

Mind as Medicine: Retreat Brings Healing, Growth

More than 100 people attended a recent meditation retreat in Tel Aviv, Israel: Physicians, journalists, holistic practitioners, cancer patients and meditation enthusiasts. They came to learn holistic, mind-body approaches to healing and find avenues to spiritual growth. The retreat was led by integrative medicine pioneer and meditation expert Isaac Eliaz, M.D., L.Ac. and was coordinated by Taatsumot, a non-profit organization. The in-depth, two-day retreat program focused on the mind's innate healing power.

Read More

Powered by ThreeSided Studios